泽布替尼对CYP3A4、CYP2C9、CYP2C19、P-gp和BCRP探针药物相互作用潜力的评估
本研究在18名健康男性志愿者中采用鸡尾酒探针法,评估泽布替尼160 mg每日两次对CYP酶和转运体的影响。结果显示泽布替尼对CYP2C9、BCRP和P-gp活性影响极小或无影响,但降低CYP3A和CYP2C19底物的全身暴露(平均降幅<50%)。
要点
- 泽布替尼对CYP2C9、BCRP和P-gp活性影响极小或无影响。
- 泽布替尼降低CYP3A和CYP2C19底物暴露,平均降幅<50%。
- 联用CYP3A或CYP2C19敏感底物时需关注暴露降低。
核心结论
- 泽布替尼320 mg日总剂量对CYP2C9、BCRP和P-gp活性影响极小或无影响,但降低CYP3A和CYP2C19底物的全身暴露(平均降幅<50%)。
研究设计与样本
- 单序列研究,18名健康男性志愿者单独口服探针药物及在泽布替尼160 mg每日两次治疗至少8天后重复给予探针药物。
主要发现
- S-华法林AUC_last几何均值比99.80%(90%CI 97.41-102.2%)。
- 咪达唑仑AUC_last几何均值比52.52%(90%CI 48.49-56.88%)。
- 地高辛AUC_last几何均值比111.3%(90%CI 103.8-119.3%)。
- 瑞舒伐他汀AUC_last几何均值比89.45%(90%CI 78.73-101.6%)。
- 奥美拉唑AUC_last几何均值比63.52%(90%CI 57.40-70.30%);Cmax观察到类似效应。
临床怎么用
- 与CYP3A或CYP2C19敏感底物联用时,需考虑泽布替尼可能降低其暴露。
- 与CYP2C9、P-gp或BCRP底物联用时,预计无需因泽布替尼调整剂量。
局限性
- 研究仅纳入健康男性志愿者,结论外推至患者人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: This study aims to assess the potential effects of zanubrutinib on the activity of cytochrome P450 (CYP) enzymes and drug transporter proteins using a cocktail probe approach. METHODS: Patients received single oral doses of probe drugs alone and after at least 8 days of treatment with zanubrutinib 160 mg twice daily in a single-sequence study in 18 healthy male volunteers. Simultaneous doses of 10 mg warfarin (CYP2C9) and 2 mg midazolam (CYP3A) were administered on Day 1 and Day 14, 0.25 mg digoxin (P-glycoprotein [P-gp]) and 10 mg rosuvastatin (breast cancer resistance protein [BCRP]) on Day 3 and Day 16, and 20 mg omeprazole (CYP2C19) on Day 5 and Day 18. Pharmacokinetic (PK) parameters were estimated from samples obtained up to 12 h post dose for zanubrutinib; 24 h for digoxin, omeprazole and midazolam; 48 h for rosuvastatin; and 144 h for warfarin. RESULTS: The ratios (%) of geometric least squares means (90% confidence intervals) for the area under the concentration-time curve from time zero to the last quantifiable concentration in the presence/absence of zanubrutinib were 99.80% (97.41-102.2%) for S-warfarin; 52.52% (48.49-56.88%) for midazolam; 111.3% (103.8-119.3%) for digoxin; 89.45% (78.73-101.6%) for rosuvastatin; and 63.52% (57.40-70.30%) for omeprazole. Similar effects were observed for maximum plasma concentrations. CONCLUSIONS: Zanubrutinib 320 mg total daily dose had minimal or no effect on the activity of CYP2C9, BCRP and P-gp, but decreased the systemic exposure of CYP3A and CYP2C19 substrates (mean reduction <50%).
引用
- Ou YC, Tang Z, Novotny W, et al. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP. Br J Clin Pharmacol. 2021. PMID: 33336408. doi:10.1111/bcp.14707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。